Generate Biomedicines Inc (GENB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$12.57-11.23%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GENB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -34.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 53.3% |
Growth built into the price is above our model estimate.
The price assumes 87.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
GENB — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securi…
Why it matters: Cash fell from $516.6 million in Q1 to $457.4 million in Q2. The company says funds cover operations into early 2028, but more capital is needed long term.
Worry ifCash falls below $457.4 million, or management shortens the runway from the first half of 2028.
Less concerning ifCash remains at or above $457.4 million and management keeps the runway into the first half of 2028.
Why it matters: The data can show whether GB-0895 is safe and active in COPD. It may guide the next step for this program.
Watch forThe Sept. 8 ERS poster reports acceptable safety and clear drug activity in the COPD study.
Also watch forThe poster reports serious safety concerns or no clear drug effect.
Why it matters: These trials test GB-0895 in severe asthma. Enrollment progress is needed before the planned 52-week outcome test.
Watch forGenerate reports continued recruitment in both trials and gives a clear path to the planned 52-week outcome test.
Also watch forGenerate reports a major recruitment delay, a trial pause, or a change to the planned study design.
Why it matters: First dosing would meet the 2026 milestone for this partnered cancer program. A delay would push back its clinical test.
Supportive ifGenerate reports that the first patient received GB-5267 in 2026.
Worry ifThe trial has not dosed its first patient by Dec. 31, 2026, or Generate reports a delay.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$263 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $914 loss on $10,000 · 9.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,068 loss on $10,000 · 40.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: GB-4362 aims to reduce MMAE-related side effects during cancer treatment. Safety results can test that goal.
Watch forThe ESMO poster reports safe use in the first study group. The group received enfortumab vedotin and pembrolizumab.
Also watch forThe poster reports serious safety issues tied to treatment or a pause in dosing.